Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK climbs as structural overhaul revealed

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline has announced new plans to get itself back on track after disappointing drug sales and a mounting number of corruption accusations across the globe. Cost reduction strategies in response to the ongoing poor performance of its respiratory portfolio helped deliver third quarter EPS of 27.9p, up 5%. GSK intends to build on this by exploring an IPO of part of ViiV Healthcare, its majority-owned joint venture HIV business, and a further £1bn savings program.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel